Improved method increases sensitivity for circulating hepatocellular carcinoma cells

World Journal of Gastroenterology

Volumn 21, Issue 10, 2015, Pages 2918-2925

  Liu, Hui Ying ^a   Qian, Hai Hua ^a   Zhang, Xiao Feng ^a   Li, Jun ^a   Yang, Xia ^a   Sun, Bin ^a   Ma, Jun Yong ^a   Chen, Lei ^a   Yin, Zheng Feng ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Asialoglycoprotein receptor; Carbamoyl phosphate synthetase 1; Circulating tumor cells; Hepatocellular carcinoma; Negative depletion

Indexed keywords

ASIALOGLYCOPROTEIN RECEPTOR; CARBAMOYL PHOSPHATE SYNTHASE; CD45 ANTIGEN; MONOCLONAL ANTIBODY; POLYLYSINE; PTPRC PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; DENSITY GRADIENT CENTRIFUGATION; FEMALE; FLOW CYTOMETRY; HEPATITIS; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LEUKOCYTE; LIVER CELL CARCINOMA; LIVER INJURY; MALE; MCF 7 CELL LINE; MIDDLE AGED; PROTEIN DEPLETION; SENSITIVITY AND SPECIFICITY; TUMOR CELL CULTURE; TUMOR CELL LINE; BLOOD; CASE CONTROL STUDY; CELL SEPARATION; COMPARATIVE STUDY; FLUORESCENT ANTIBODY TECHNIQUE; LIVER TUMOR; METABOLISM; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; TUMOR EMBOLISM;

ANTIGENS, CD45; ASIALOGLYCOPROTEIN RECEPTOR; BIOMARKERS, TUMOR; CARBAMOYL-PHOSPHATE SYNTHASE (AMMONIA); CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CELL SEPARATION; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MCF-7 CELLS; NEOPLASTIC CELLS, CIRCULATING; REPRODUCIBILITY OF RESULTS;

EID: 84924931647     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i10.2918     Document Type: Article

References (37)

1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-1273.e1 [PMID: 22537432 DOI: 10.1053/j.gastro.2011.12.061]
2. Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol 2014; 20: 4115-4127 [PMID: 24764650]
3. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-1491 [PMID: 19224838 DOI: 10.1200/JCO.2008.20.7753]
4. Adam R, Azoulay D, Castaing D, Eshkenazy R, Pascal G, Hashizume K, Samuel D, Bismuth H. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann Surg 2003; 238: 508-518; discussion 518-519 [PMID: 14530722]
5. Regimbeau JM, Abdalla EK, Vauthey JN, Lauwers GY, Durand F, Nagorney DM, Ikai I, Yamaoka Y, Belghiti J. Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma: results of a multicenter study. J Surg Oncol 2004; 85: 36-41 [PMID: 14696085 DOI: 10.1002/jso.10284]
6. Alix-Panabières C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem 2013; 59: 110-118 [PMID: 23014601 DOI: 10.1373/clinchem.2012.194258]
7. Nguyen DX, Bos PD, Massagué J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9: 274-284 [PMID: 19308067 DOI: 10.1038/nrc2622]
8. Zhang Y, Li J, Cao L, Xu W, Yin Z. Circulating tumor cells in hepatocellular carcinoma: detection techniques, clinical implications, and future perspectives. Semin Oncol 2012; 39: 449-460 [PMID: 22846862 DOI: 10.1053/j.seminoncol.2012.05.012]
9. Zhang Y, Shi ZL, Yang X, Yin ZF. Targeting of circulating hepatocellular carcinoma cells to prevent postoperative recurrence and metastasis. World J Gastroenterol 2014; 20: 142-147 [PMID: 24415867 DOI: 10.3748/wjg.v20.i1.142]
10. Gorges TM, Pantel K. Circulating tumor cells as therapy-related biomarkers in cancer patients. Cancer Immunol Immunother 2013; 62: 931-939 [PMID: 23314304 DOI: 10.1007/s00262-012-1387-1]
11. Lianidou ES, Markou A, Strati A. Molecular characterization of circulating tumor cells in breast cancer: challenges and promises for individualized cancer treatment. Cancer Metastasis Rev 2012; 31: 663-671 [PMID: 22692478 DOI: 10.1007/s10555-012-9366-8]
12. Liu H, Zhang X, Li J, Sun B, Qian H, Yin Z. The biological and clinical importance of epithelial-mesenchymal transition in circulating tumor cells. J Cancer Res Clin Oncol 2015; 141: 189-201 [PMID: 24965746 DOI: 10.1007/s00432-014-1752-x]
13. Jacob K, Sollier C, Jabado N. Circulating tumor cells: detection, molecular profiling and future prospects. Expert Rev Proteomics 2007; 4: 741-756 [PMID: 18067413 DOI: 10.1586/14789450.4.6.741]
14. Attard G, de Bono JS. Utilizing circulating tumor cells: challenges and pitfalls. Curr Opin Genet Dev 2011; 21: 50-58 [PMID: 21112767 DOI: 10.1016/j.gde.2010.10.010]
15. de Boer CJ, van Krieken JH, Janssen-van Rhijn CM, Litvinov SV. Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver. J Pathol 1999; 188: 201-206 [PMID: 10398165 DOI: 10.1002/(SICI)1096-9896(199906)188]
16. Proca DM, Niemann TH, Porcell AI, DeYoung BR. MOC31 immunoreactivity in primary and metastatic carcinoma of the liver. Report of findings and review of other utilized markers. Appl Immunohistochem Mol Morphol 2000; 8: 120-125 [PMID: 10937059]
17. Porcell AI, De Young BR, Proca DM, Frankel WL. Immunohistochemical analysis of hepatocellular and adenocarcinoma in the liver: MOC31 compares favorably with other putative markers. Mod Pathol 2000; 13: 773-778 [PMID: 10912937]
18. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S. Frequent EpCam protein expression in human carcinomas. Hum Pathol 2004; 35: 122-128 [PMID: 14745734 DOI: 10.1016/j.humpath.2003.08.026]
19. Sun YF, Xu Y, Yang XR, Guo W, Zhang X, Qiu SJ, Shi RY, Hu B, Zhou J, Fan J. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology 2013; 57: 1458-1468 [PMID: 23175471 DOI: 10.1002/hep.26151]
20. Schulze K, Gasch C, Staufer K, Nashan B, Lohse AW, Pantel K, Riethdorf S, Wege H. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer 2013; 133: 2165-2171 [PMID: 23616258 DOI: 10.1002/ijc.28230]
21. Morris KL, Tugwood JD, Khoja L, Lancashire M, Sloane R, Burt D, Shenjere P, Zhou C, Hodgson C, Ohtomo T, Katoh A, Ishiguro T, Valle JW, Dive C. Circulating biomarkers in hepatocellular carcinoma. Cancer Chemother Pharmacol 2014; 74: 323-332 [PMID: 24923562 DOI: 10.1007/s00280-014-2508-7]
22. Xu W, Cao L, Chen L, Li J, Zhang XF, Qian HH, Kang XY, Zhang Y, Liao J, Shi LH, Yang YF, Wu MC, Yin ZF. Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategy. Clin Cancer Res 2011; 17: 3783-3793 [PMID: 21527564 DOI: 10.1158/1078-0432]
23. Li J, Chen L, Zhang X, Zhang Y, Liu H, Sun B, Zhao L, Ge N, Qian H, Yang Y, Wu M, Yin Z. Detection of circulating tumor cells in hepatocellular carcinoma using antibodies against asialoglycoprotein receptor, carbamoyl phosphate synthetase 1 and pan-cytokeratin. PLoS One 2014; 9: e96185 [PMID: 24763545 DOI: 10.1371/journal.pone.0096185]
24. Stockert RJ, Morell AG. Hepatic binding protein: the galactose-specific receptor of mammalian hepatocytes. Hepatology 1983; 3: 750-757 [PMID: 6413351 DOI: 10.1002/hep]
25. Ashwell G, Morell AG. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv Enzymol Relat Areas Mol Biol 1974; 41: 99-128 [PMID: 4609051 DOI: 10.1002/9780470122860.ch3]
26. Hyodo I, Mizuno M, Yamada G, Tsuji T. Distribution of asialoglycoprotein receptor in human hepatocellular carcinoma. Liver 1993; 13: 80-85 [PMID: 8389955 DOI: 10.1111/j.1600-0676.1993.tb00611.x]
27. Trerè D, Fiume L, De Giorgi LB, Di Stefano G, Migaldi M, Derenzini M. The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells. Br J Cancer 1999; 81: 404-408 [PMID: 10507763 DOI: 10.1038/sj.bjc]
28. Shi B, Abrams M, Sepp-Lorenzino L. Expres s ion of asialoglycoprotein receptor 1 in human hepatocellular carcinoma. J Histochem Cytochem 2013; 61: 901-909 [PMID: 23979840 DOI: 10.1369/0022155413503662]
29. Butler SL, Dong H, Cardona D, Jia M, Zheng R, Zhu H, Crawford JM, Liu C. The antigen for Hep Par 1 antibody is the urea cycle enzyme carbamoyl phosphate synthetase 1. Lab Invest 2008; 88: 78-88 [PMID: 18026163 DOI: 10.1038/labinvest.3700699]
30. Lustberg M, Jatana KR, Zborowski M, Chalmers JJ. Emerging technologies for CTC detection based on depletion of normal cells. Recent Results Cancer Res 2012; 195: 97-110 [PMID: 22527498 DOI: 10.1007/978-3-642-28160-0-9]
31. Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulias V, Agelaki S. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res 2011; 13: R59 [PMID: 21663619 DOI: 10.1186/bcr2896]
32. Balasubramanian P, Lang JC, Jatana KR, Miller B, Ozer E, Old M, Schuller DE, Agrawal A, Teknos TN, Summers TA, Lustberg MB, Zborowski M, Chalmers JJ. Multiparameter analysis, including EMT markers, on negatively enriched blood samples from patients with squamous cell carcinoma of the head and neck. PLoS One 2012; 7: e42048 [PMID: 22844540 DOI: 10.1371/journal.pone.0042048]
33. Guo J, Yao F, Lou Y, Xu C, Xiao B, Zhou W, Chen J, Hu Y, Liu Z. Detecting carcinoma cells in peripheral blood of patients with hepatocellular carcinoma by immunomagnetic beads and rt-PCR. J Clin Gastroenterol 2007; 41: 783-788 [PMID: 17700428 DOI: 10.1097/01.mcg]
34. Wu C, Hao H, Li L, Zhou X, Guo Z, Zhang L, Zhang X, Zhong W, Guo H, Bremner RM, Lin P. Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients. J Thorac Oncol 2009; 4: 30-36 [PMID: 19096303 DOI: 10.1097/JTO.0b013e3181914125]
35. Liu H, Dong H, Robertson K, Liu C. DNA methylation suppresses expression of the urea cycle enzyme carbamoyl phosphate synthetase 1 (CPS1) in human hepatocellular carcinoma. Am J Pathol 2011; 178: 652-661 [PMID: 21281797 DOI: 10.1016/j.ajpath.2010.10.023]
36. Siddiqui MT, Saboorian MH, Gokaslan ST, Ashfaq R. Diagnostic utility of the HepPar1 antibody to differentiate hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration samples. Cancer 2002; 96: 49-52 [PMID: 11836703 DOI: 10.1002/cncr.10311]
37. Timek DT, Shi J, Liu H, Lin F. Arginase-1, HepPar-1, and Glypican-3 are the most effective panel of markers in distinguishing hepatocellular carcinoma from metastatic tumor on fine-needle aspiration specimens. Am J Clin Pathol 2012; 138: 203-210 [PMID: 22904131 DOI: 10.1309/AJCPK1ZC9WNHCCMU]